EDAP TMS (EDAP) 2025 Conference June 05, 2025 04:20 PM ET Speaker0 Okay. Alright. Good afternoon. My name is Michael Sarcone. I'm an analyst on the US Medical Supplies and Devices team, this is day two of the Jefferies twenty twenty five New York Healthcare Conference. This is a session with EDAP Focal One. And with us from the company, we've got Ryan Rhodes, CEO Ken Moback, CFO and John Francis who heads the IR function. Ryan Rhodes is going to give a presentation, some prepared commentary and then we'll o ...

I-Mab (IMAB) 2025 Conference June 05, 2025 03:45 PM ET Speaker0 Great. I think we can get started. Good afternoon, everyone. Thank you for attending Jefferies Healthcare Conference. My name is Yifan Shi from Jefferies Biotech Research Team. Today, we are very pleased to have Doctor. Sheng Fu, CEO of IMAP, and Doctor. Philip Dennis, CMO of IMAP, in for this session. Welcome. Speaker1 Thank you. Speaker0 So, to get start, so for those who may be less familiar with your story, could you please provide a high l ...

CytomX Therapeutics (CTMX) 2025 Conference June 05, 2025 02:35 PM ET Speaker0 All right. All right. Welcome, everyone, to Jefferies twenty twenty five Global Healthcare Conference. My name is Roger Sung, one of the senior analysts cover SMICHA Biotech in The US. It is my pleasure to have the next fireside chat with Atomic Therapeutics CEO, Sean. Good. Yeah. Good to see you. Speaker1 Pleasure to be here, Roger. Speaker0 Awesome. Maybe before we start, we know you just announced a very exciting data from your ...

Lexeo Therapeutics (LXEO) Conference June 05, 2025 02:00 PM ET Speaker0 Available to clients in this call. If the company is presenting, any recording may also be posted on their website. Usually, the opinion discussed by any experts speaking on this call are those who are speaking and not to check for Morgan. After this conference call, we will also be and participants now. I would now like to turn the call over to Tess Romero to begin. Please go ahead when you're ready. Speaker1 Thank you, operator, and t ...

CareDx (CDNA) 2025 Conference June 05, 2025 10:30 AM ET Speaker0 Good morning. I'm John Hanna, the president and CEO at CareDx. Thank you all for joining us today. This is our safe harbor statement. We may make forward looking statements during the presentation. Please refer to the safe harbor on our website. At CareDx we've built an experienced leadership team in the molecular diagnostics market to drive profitable growth. We have six fifty employees globally, 180 driving our commercial growth in the marke ...

Key Takeaways FDA grants platform tech designation to SRPT's rAAVrh74 viral vector used in SRP-9003 The tag lets Sarepta reuse clinical and manufacturing data across other rAAVrh74-based therapies. SRP-9003 is in a phase III trial for LGMD2E/R4; data expected later this month.Sarepta Therapeutics (SRPT) announced that the FDA has granted platform-technology designation to its viral vector rAAVrh74, used in the investigational gene therapy SRP-9003. This therapy is being evaluated in a late-stage study for ...

RGX-202: AFFINITY DUCHENNE® New Phase I/II Interim Functional Data June 2025 Forward-looking statements This presentation includes "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as "believe," "may," "will," "estimate," "continue," " ...

New appointments of Drs. Philip C. Amrein and Alex Kentsis Validate Lead Galinpepimut-S and SLS009 Programs as Company Approaches Key Inflection Points This YearNEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the appointment of two distinguished oncology leaders to its Scientific Advisor ...

Core Viewpoint - Cocrystal Pharma, Inc. is presenting its broad-spectrum protease inhibitor CDI-988 at the 2025 Military Health System Research Symposium, highlighting its potential as a prophylaxis and treatment for norovirus, which currently lacks approved antiviral agents or vaccines [1][2]. Company Overview - Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics targeting the replication processes of various viruses, including noroviruses, coronaviruses, and hepatitis C viruses [6]. - The company utilizes unique structure-based technologies and expertise in enzymology and medicinal chemistry to create first- and best-in-class antiviral drugs [6]. Product Development - CDI-988 is designed as a broad-spectrum inhibitor targeting a highly conserved region in the active site of 3CL viral proteases, representing a first-in-class oral treatment for noroviruses and coronaviruses [3]. - The company has completed a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of CDI-988 in healthy adults, which included a food effect cohort [3]. Technology Platform - Cocrystal's proprietary structure-based platform technology provides a three-dimensional structure of inhibitor complexes at near-atomic resolution, facilitating the identification of novel binding sites and rapid structural information processing [4]. - The goal of this technology is to develop antiviral therapies that are safe, well-tolerated, and effective against all viral subtypes, with a high barrier to viral resistance [4]. Industry Context - The Military Health System Research Symposium is an annual event that gathers military medical care providers, researchers, and industry representatives to discuss healthcare initiatives related to military infectious diseases and operational medicine [5].

Company Overview - NewAmsterdam Pharma Company N.V. is a late-stage clinical biopharmaceutical company focused on developing oral, non-statin medicines for patients at risk of cardiovascular disease (CVD) with elevated low-density lipoprotein cholesterol (LDL-C) [1][5] - The company aims to address the unmet need for safe, well-tolerated, and convenient LDL-lowering therapies, particularly for patients who do not respond adequately to existing treatments [5] R&D Day Announcement - NewAmsterdam will host an R&D Day event for analysts and investors on June 11, 2025, at 9:00 a.m. ET in New York City [1] - The event will feature key members of the management team, including the CEO and Chief Scientific Officer [2] Obicetrapib Development - Obicetrapib is a novel, oral, low-dose CETP inhibitor being developed by NewAmsterdam to improve LDL-lowering treatment outcomes [4] - The company has conducted multiple Phase 2 and Phase 3 trials, demonstrating statistically significant LDL-lowering effects with a side effect profile similar to placebo [4] - The Phase 3 PREVAIL CVOT trial, which commenced in March 2022, has enrolled over 9,500 patients to assess obicetrapib's potential in reducing major adverse cardiovascular events (MACE) [4] Commercialization Rights - The commercialization rights for obicetrapib in Europe have been exclusively granted to the Menarini Group, a leading international pharmaceutical and diagnostics company [4]